| 3.72 -0.435 (-10.47%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.68 | 1-year : | 6.94 |
| Resists | First : | 4.86 | Second : | 5.94 |
| Pivot price | 4.7  |
|||
| Supports | First : | 3.11 | Second : | 2.59 |
| MAs | MA(5) : | 4.28 |
MA(20) : | 4.58 |
| MA(100) : | 4.54 |
MA(250) : | 2.74  |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 22 |
D(3) : | 37 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 19.29 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SONN ] has closed above bottom band by 3.6%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.24 - 4.27 | 4.27 - 4.29 |
| Low: | 3.51 - 3.54 | 3.54 - 3.56 |
| Close: | 4.11 - 4.16 | 4.16 - 4.2 |
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Tue, 18 Nov 2025
Sonnet BioTherapeutics (SONN) Delays Shareholder Vote on Key Bus - GuruFocus
Tue, 18 Nov 2025
Sonnet Bio (NASDAQ: SONN) gets 95% support as merger vote delayed to Dec 2025 - Stock Titan
Mon, 27 Oct 2025
Sonnet BioTherapeutics Announces Special Meeting for Business Combination Vote - TipRanks
Mon, 14 Jul 2025
Sonnet BioTherapeutics, Inc. Stock Soars 218% Amid $888M Hyperliquid Merger Deal - CoinCentral
Mon, 14 Jul 2025
Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant - Stocktwits
Mon, 14 Jul 2025
Sonnet BioTherapeutics jumps over 320%, combines business for HYPE crypto reserve (SONN:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 6.74e+006 (%) |
| Held by Institutions | 4.2 (%) |
| Shares Short | 2,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.405e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 405.8 % |
| Return on Equity (ttm) | -223.9 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -522129 |
| Qtrly Earnings Growth | -6.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.01 |
| Dividend | 0 |
| Forward Dividend | 2.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|